A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis

B. Elewski, R. Pollak, S. Ashton, Phoebe Rich, J. Schlessinger, A. Tavakkol

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Summary Background Onychomycosis accounts for up to 50% of all onychopathies. Objectives To evaluate the efficacy of four posaconazole regimens compared with placebo in the treatment of toenail onychomycosis, to assess the safety and tolerability of posaconazole, and to estimate the relative efficacy of posaconazole against terbinafine. Methods A phase 2B, randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded (double blind for placebo) study (ClinicalTrials.gov identifier: NCT00491764). Onychomycosis patients aged 18-75 years (n = 218) were randomized equally to one of six treatment regimens: posaconazole (oral suspension) 100, 200 or 400 mg once daily (24 weeks); posaconazole 400 mg once daily (12 weeks); terbinafine (tablets) 250 mg once daily (12 weeks); or placebo (24 weeks). The primary efficacy variable was complete cure (negative mycology and 0% nail involvement) at week 48. Results All posaconazole treatment arms had a significantly (P & 0·012) greater proportion of patients with complete cure at week 48 compared with placebo. The proportions of patients with complete cure were numerically higher for posaconazole 200 mg/24 weeks (54·1%) and 400 mg/24 weeks (45·5%), but lower for 400 mg/12 weeks (20%) compared with terbinafine (37%; differences were not statistically significant). Posaconazole was well tolerated. Seven patients receiving posaconazole withdrew because of asymptomatic liver enzyme increases, as mandated by protocol discontinuation criteria. Conclusions The efficacy and favourable safety profile of posaconazole suggest a potential new treatment for onychomycosis. The availability of low-cost generic terbinafine may limit posaconazole use to second-line treatment of infections refractory to, or patients intolerant of, terbinafine, or nondermatophyte mould infections.

Original languageEnglish (US)
Pages (from-to)389-398
Number of pages10
JournalBritish Journal of Dermatology
Volume166
Issue number2
DOIs
StatePublished - Jan 1 2012

Fingerprint

Onychomycosis
terbinafine
Nails
Placebos
Research Personnel
Therapeutics
posaconazole
Mycology
Safety
Infection
Double-Blind Method
Tablets
Suspensions
Fungi

ASJC Scopus subject areas

  • Dermatology

Cite this

A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. / Elewski, B.; Pollak, R.; Ashton, S.; Rich, Phoebe; Schlessinger, J.; Tavakkol, A.

In: British Journal of Dermatology, Vol. 166, No. 2, 01.01.2012, p. 389-398.

Research output: Contribution to journalArticle

@article{4590ef386bdf430d8c14daa519cf788d,
title = "A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis",
abstract = "Summary Background Onychomycosis accounts for up to 50{\%} of all onychopathies. Objectives To evaluate the efficacy of four posaconazole regimens compared with placebo in the treatment of toenail onychomycosis, to assess the safety and tolerability of posaconazole, and to estimate the relative efficacy of posaconazole against terbinafine. Methods A phase 2B, randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded (double blind for placebo) study (ClinicalTrials.gov identifier: NCT00491764). Onychomycosis patients aged 18-75 years (n = 218) were randomized equally to one of six treatment regimens: posaconazole (oral suspension) 100, 200 or 400 mg once daily (24 weeks); posaconazole 400 mg once daily (12 weeks); terbinafine (tablets) 250 mg once daily (12 weeks); or placebo (24 weeks). The primary efficacy variable was complete cure (negative mycology and 0{\%} nail involvement) at week 48. Results All posaconazole treatment arms had a significantly (P & 0·012) greater proportion of patients with complete cure at week 48 compared with placebo. The proportions of patients with complete cure were numerically higher for posaconazole 200 mg/24 weeks (54·1{\%}) and 400 mg/24 weeks (45·5{\%}), but lower for 400 mg/12 weeks (20{\%}) compared with terbinafine (37{\%}; differences were not statistically significant). Posaconazole was well tolerated. Seven patients receiving posaconazole withdrew because of asymptomatic liver enzyme increases, as mandated by protocol discontinuation criteria. Conclusions The efficacy and favourable safety profile of posaconazole suggest a potential new treatment for onychomycosis. The availability of low-cost generic terbinafine may limit posaconazole use to second-line treatment of infections refractory to, or patients intolerant of, terbinafine, or nondermatophyte mould infections.",
author = "B. Elewski and R. Pollak and S. Ashton and Phoebe Rich and J. Schlessinger and A. Tavakkol",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1365-2133.2011.10660.x",
language = "English (US)",
volume = "166",
pages = "389--398",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis

AU - Elewski, B.

AU - Pollak, R.

AU - Ashton, S.

AU - Rich, Phoebe

AU - Schlessinger, J.

AU - Tavakkol, A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Summary Background Onychomycosis accounts for up to 50% of all onychopathies. Objectives To evaluate the efficacy of four posaconazole regimens compared with placebo in the treatment of toenail onychomycosis, to assess the safety and tolerability of posaconazole, and to estimate the relative efficacy of posaconazole against terbinafine. Methods A phase 2B, randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded (double blind for placebo) study (ClinicalTrials.gov identifier: NCT00491764). Onychomycosis patients aged 18-75 years (n = 218) were randomized equally to one of six treatment regimens: posaconazole (oral suspension) 100, 200 or 400 mg once daily (24 weeks); posaconazole 400 mg once daily (12 weeks); terbinafine (tablets) 250 mg once daily (12 weeks); or placebo (24 weeks). The primary efficacy variable was complete cure (negative mycology and 0% nail involvement) at week 48. Results All posaconazole treatment arms had a significantly (P & 0·012) greater proportion of patients with complete cure at week 48 compared with placebo. The proportions of patients with complete cure were numerically higher for posaconazole 200 mg/24 weeks (54·1%) and 400 mg/24 weeks (45·5%), but lower for 400 mg/12 weeks (20%) compared with terbinafine (37%; differences were not statistically significant). Posaconazole was well tolerated. Seven patients receiving posaconazole withdrew because of asymptomatic liver enzyme increases, as mandated by protocol discontinuation criteria. Conclusions The efficacy and favourable safety profile of posaconazole suggest a potential new treatment for onychomycosis. The availability of low-cost generic terbinafine may limit posaconazole use to second-line treatment of infections refractory to, or patients intolerant of, terbinafine, or nondermatophyte mould infections.

AB - Summary Background Onychomycosis accounts for up to 50% of all onychopathies. Objectives To evaluate the efficacy of four posaconazole regimens compared with placebo in the treatment of toenail onychomycosis, to assess the safety and tolerability of posaconazole, and to estimate the relative efficacy of posaconazole against terbinafine. Methods A phase 2B, randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded (double blind for placebo) study (ClinicalTrials.gov identifier: NCT00491764). Onychomycosis patients aged 18-75 years (n = 218) were randomized equally to one of six treatment regimens: posaconazole (oral suspension) 100, 200 or 400 mg once daily (24 weeks); posaconazole 400 mg once daily (12 weeks); terbinafine (tablets) 250 mg once daily (12 weeks); or placebo (24 weeks). The primary efficacy variable was complete cure (negative mycology and 0% nail involvement) at week 48. Results All posaconazole treatment arms had a significantly (P & 0·012) greater proportion of patients with complete cure at week 48 compared with placebo. The proportions of patients with complete cure were numerically higher for posaconazole 200 mg/24 weeks (54·1%) and 400 mg/24 weeks (45·5%), but lower for 400 mg/12 weeks (20%) compared with terbinafine (37%; differences were not statistically significant). Posaconazole was well tolerated. Seven patients receiving posaconazole withdrew because of asymptomatic liver enzyme increases, as mandated by protocol discontinuation criteria. Conclusions The efficacy and favourable safety profile of posaconazole suggest a potential new treatment for onychomycosis. The availability of low-cost generic terbinafine may limit posaconazole use to second-line treatment of infections refractory to, or patients intolerant of, terbinafine, or nondermatophyte mould infections.

UR - http://www.scopus.com/inward/record.url?scp=84856230680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856230680&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2011.10660.x

DO - 10.1111/j.1365-2133.2011.10660.x

M3 - Article

VL - 166

SP - 389

EP - 398

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -